{"name": "Provesica",
 "permalink": "provesica",
 "crunchbase_url": "http://www.crunchbase.com/company/provesica",
 "homepage_url": "http://www.provesica.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": null,
 "number_of_employees": null,
 "founded_year": 2010,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@provesica.com",
 "phone_number": "+44 (0)1223 493900",
 "description": "biopharmaceutical company",
 "created_at": "Mon Dec 20 17:20:50 UTC 2010",
 "updated_at": "Mon Dec 20 17:52:53 UTC 2010",
 "overview": "\u003Cp\u003EProvesica is a Cambridge-based biopharmaceutical company specialising in overactive bladder. The Company\u00e2\u20ac\u2122s development compound, XEN-D0501, is highly potent antagonist of the vanilloid receptor, TRPV1, and is about to start Phase 2 clinical development.\u003C/p\u003E\n\n\u003Cp\u003EIn addition to XEN-D0501, Provesica owns a portfolio of intellectual property covering diverse TRPV1 antagonists suitable for development in overactive bladder or other indications where TRPV1 has been validated as an intervention target.\u003C/p\u003E\n\n\u003Cp\u003EProvesica was established in 2010 following the demerger of the overactive bladder and TRPV1 interests of Xention Ltd, an ion channel specialist drug discovery and development company.  Provesica has so far raised \u00c2\u00a34 million in finance to progress its lead programme through Phase 2 development.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       47],
      "assets/images/resized/0011/4776/114776v1-max-150x150.png"],
     [[250,
       78],
      "assets/images/resized/0011/4776/114776v1-max-250x250.png"],
     [[305,
       96],
      "assets/images/resized/0011/4776/114776v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chairman ",
    "person":
     {"first_name": "Keith",
      "last_name": "G McCullagh",
      "permalink": "keith-g-mccullagh",
      "image":
       {"available_sizes":
         [[[113,
            150],
           "assets/images/resized/0011/4778/114778v1-max-150x150.jpg"],
          [[113,
            150],
           "assets/images/resized/0011/4778/114778v1-max-250x250.jpg"],
          [[113,
            150],
           "assets/images/resized/0011/4778/114778v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": false,
    "title": "Executive Vice President",
    "person":
     {"first_name": "Wolfgang",
      "last_name": "Hartwig",
      "permalink": "wolfgang-hartwig",
      "image":
       {"available_sizes":
         [[[113,
            150],
           "assets/images/resized/0011/4779/114779v1-max-150x150.jpg"],
          [[113,
            150],
           "assets/images/resized/0011/4779/114779v1-max-250x250.jpg"],
          [[113,
            150],
           "assets/images/resized/0011/4779/114779v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "\u20ac4.7M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.seroba-kernel.com/news/december16_10.html",
    "source_description": "Seroba Kernel Announces \u00e2\u201a\u00ac4.7m Financing into Provesica to Complete Phase 2 Trial for Overactive Bladder ",
    "raised_amount": 4700000.0,
    "raised_currency_code": "EUR",
    "funded_year": 2010,
    "funded_month": 12,
    "funded_day": 20,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Seroba Kernel",
         "permalink": "seroba-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               34],
              "assets/images/resized/0007/6008/76008v2-max-150x150.png"],
             [[250,
               57],
              "assets/images/resized/0007/6008/76008v2-max-250x250.png"],
             [[274,
               63],
              "assets/images/resized/0007/6008/76008v2-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "HQ",
    "address1": "Iconix Park ",
    "address2": "London Road ",
    "zip_code": "CB22 3EG  ",
    "city": "Cambridge",
    "state_code": null,
    "country_code": "GBR",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        114],
       "assets/images/resized/0011/4777/114777v1-max-150x150.jpg"],
      [[250,
        190],
       "assets/images/resized/0011/4777/114777v1-max-250x250.jpg"],
      [[450,
        343],
       "assets/images/resized/0011/4777/114777v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}